These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 25665652)

  • 1. Theoretical analysis of the binding of potential inhibitors to protein kinases MK2 and MK3.
    Araújo PM; da Silva LP; Esteves da Silva JC
    Med Chem; 2015; 11(6):573-9. PubMed ID: 25665652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2,4-Diaminopyrimidine MK2 inhibitors. Part I: Observation of an unexpected inhibitor binding mode.
    Argiriadi MA; Ericsson AM; Harris CM; Banach DL; Borhani DW; Calderwood DJ; Demers MD; Dimauro J; Dixon RW; Hardman J; Kwak S; Li B; Mankovich JA; Marcotte D; Mullen KD; Ni B; Pietras M; Sadhukhan R; Sousa S; Tomlinson MJ; Wang L; Xiang T; Talanian RV
    Bioorg Med Chem Lett; 2010 Jan; 20(1):330-3. PubMed ID: 19919896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potency switch between CHK1 and MK2: discovery of imidazo[1,2-a]pyrazine- and imidazo[1,2-c]pyrimidine-based kinase inhibitors.
    Meng Z; Ciavarri JP; McRiner A; Zhao Y; Zhao L; Reddy PA; Zhang X; Fischmann TO; Whitehurst C; Arshad Siddiqui M
    Bioorg Med Chem Lett; 2013 May; 23(10):2863-7. PubMed ID: 23587425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural analysis of an MK2-inhibitor complex: insight into the regulation of the secondary structure of the Gly-rich loop by TEI-I01800.
    Fujino A; Fukushima K; Namiki N; Kosugi T; Takimoto-Kamimura M
    Acta Crystallogr D Biol Crystallogr; 2010 Jan; 66(Pt 1):80-7. PubMed ID: 20057052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the putative binding conformation of a pyrazolopyridine class of inhibitors of MAPKAPK2 using computational studies.
    Miglani R; Cliffe IA; Voleti SR
    Eur J Med Chem; 2010 Jan; 45(1):98-105. PubMed ID: 19850376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformation constraint of anilides enabling the discovery of tricyclic lactams as potent MK2 non-ATP competitive inhibitors.
    Xiao D; Palani A; Huang X; Sofolarides M; Zhou W; Chen X; Aslanian R; Guo Z; Fossetta J; Tian F; Trivedi P; Spacciapoli P; Whitehurst CE; Lundell D
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3262-6. PubMed ID: 23602398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological and genetic inhibition of downstream targets of p38 MAPK in experimental nephrotic syndrome.
    Nie X; Chanley MA; Pengal R; Thomas DB; Agrawal S; Smoyer WE
    Am J Physiol Renal Physiol; 2018 Apr; 314(4):F602-F613. PubMed ID: 29187369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-based lead identification of ATP-competitive MK2 inhibitors.
    Barf T; Kaptein A; de Wilde S; van der Heijden R; van Someren R; Demont D; Schultz-Fademrecht C; Versteegh J; van Zeeland M; Seegers N; Kazemier B; van de Kar B; van Hoek M; de Roos J; Klop H; Smeets R; Hofstra C; Hornberg J; Oubrie A
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3818-22. PubMed ID: 21565500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Facile synthesis of tetracyclic azepine and oxazocine derivatives and their potential as MAPKAP-K2 (MK2) inhibitors.
    Rao AU; Xiao D; Huang X; Zhou W; Fossetta J; Lundell D; Tian F; Trivedi P; Aslanian R; Palani A
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1068-72. PubMed ID: 22182499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-Anilino-6-phenyl-quinoline inhibitors of mitogen activated protein kinase-activated protein kinase 2 (MK2).
    Olsson H; Sjö P; Ersoy O; Kristoffersson A; Larsson J; Nordén B
    Bioorg Med Chem Lett; 2010 Aug; 20(16):4738-40. PubMed ID: 20643547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and in vivo activity of MK2 and MK2 substrate-selective p38alpha(MAPK) inhibitors in Werner syndrome cells.
    Davis T; Bagley MC; Dix MC; Murziani PG; Rokicki MJ; Widdowson CS; Zayed JM; Bachler MA; Kipling D
    Bioorg Med Chem Lett; 2007 Dec; 17(24):6832-5. PubMed ID: 17964780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of a novel series of potent MK2 non-ATP competitive inhibitors using 1,2-substituted azoles as cis-amide isosteres.
    Xiao D; Zhu X; Sofolarides M; Degrado S; Shao N; Rao A; Chen X; Aslanian R; Fossetta J; Tian F; Trivedi P; Lundell D; Palani A
    Bioorg Med Chem Lett; 2014 Aug; 24(15):3609-13. PubMed ID: 24913714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization.
    Harris CM; Ericsson AM; Argiriadi MA; Barberis C; Borhani DW; Burchat A; Calderwood DJ; Cunha GA; Dixon RW; Frank KE; Johnson EF; Kamens J; Kwak S; Li B; Mullen KD; Perron DC; Wang L; Wishart N; Wu X; Zhang X; Zmetra TR; Talanian RV
    Bioorg Med Chem Lett; 2010 Jan; 20(1):334-7. PubMed ID: 19926477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part I.
    Revesz L; Schlapbach A; Aichholz R; Feifel R; Hawtin S; Heng R; Hiestand P; Jahnke W; Koch G; Kroemer M; Möbitz H; Scheufler C; Velcicky J; Huppertz C
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4715-8. PubMed ID: 20594847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part II.
    Revesz L; Schlapbach A; Aichholz R; Dawson J; Feifel R; Hawtin S; Littlewood-Evans A; Koch G; Kroemer M; Möbitz H; Scheufler C; Velcicky J; Huppertz C
    Bioorg Med Chem Lett; 2010 Aug; 20(15):4719-23. PubMed ID: 20591669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A three-step protocol for lead optimization: quick identification of key conformational features and functional groups in the SAR studies of non-ATP competitive MK2 (MAPKAPK2) inhibitors.
    Huang X; Zhu X; Chen X; Zhou W; Xiao D; Degrado S; Aslanian R; Fossetta J; Lundell D; Tian F; Trivedi P; Palani A
    Bioorg Med Chem Lett; 2012 Jan; 22(1):65-70. PubMed ID: 22169260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine regulation by MAPK activated kinase 2 in keratinocytes exposed to sulfur mustard.
    Yego EC; Dillman JF
    Toxicol In Vitro; 2013 Oct; 27(7):2067-75. PubMed ID: 23851002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MAPKAPK2, MK2): Medicinal Chemistry Efforts To Lead Small Molecule Inhibitors to Clinical Trials.
    Fiore M; Forli S; Manetti F
    J Med Chem; 2016 Apr; 59(8):3609-34. PubMed ID: 26502061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endoplasmic reticulum-associated ubiquitin-conjugating enzyme Ube2j1 is a novel substrate of MK2 (MAPKAP kinase-2) involved in MK2-mediated TNFα production.
    Menon MB; Tiedje C; Lafera J; Ronkina N; Konen T; Kotlyarov A; Gaestel M
    Biochem J; 2013 Dec; 456(2):163-72. PubMed ID: 24020373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the Water Network in Cyclin G-Associated Kinase (GAK) with 4-Anilino-quin(az)oline Inhibitors.
    Asquith CRM; Tizzard GJ; Bennett JM; Wells CI; Elkins JM; Willson TM; Poso A; Laitinen T
    ChemMedChem; 2020 Jul; 15(13):1200-1215. PubMed ID: 32358915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.